ValuEngine upgraded shares of Myriad Genetics, Inc. (NASDAQ:MYGN) from a hold rating to a buy rating in a research note released on Friday.

A number of other research analysts have also recently commented on the stock. Deutsche Bank AG boosted their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a hold rating in a research report on Wednesday, November 8th. Morgan Stanley boosted their target price on shares of Myriad Genetics from $24.00 to $26.00 and gave the stock an underweight rating in a research report on Wednesday, November 8th. Zacks Investment Research raised shares of Myriad Genetics from a hold rating to a strong-buy rating and set a $42.00 target price on the stock in a research report on Tuesday, October 17th. Leerink Swann reissued a market perform rating and set a $31.00 target price on shares of Myriad Genetics in a research report on Monday, October 2nd. Finally, Stephens reissued an overweight rating and set a $40.00 target price (up from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $28.10.

Myriad Genetics (NASDAQ:MYGN) opened at $32.47 on Friday. The firm has a market cap of $2,184.55, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm had revenue of $190.20 million for the quarter, compared to analysts’ expectations of $183.52 million. During the same period in the previous year, the company posted $0.23 earnings per share. Myriad Genetics’s revenue was up 7.2% compared to the same quarter last year. equities research analysts predict that Myriad Genetics will post 1.04 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics, Inc. (MYGN) Upgraded to “Buy” by ValuEngine” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/myriad-genetics-inc-mygn-upgraded-to-buy-by-valuengine/1702337.html.

In related news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction on Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the sale, the director now owns 52,524 shares in the company, valued at $1,591,477.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.70% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Myriad Genetics by 168,335.7% during the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock valued at $183,203,000 after purchasing an additional 9,536,219 shares during the last quarter. Vanguard Group Inc. increased its stake in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after purchasing an additional 56,708 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Myriad Genetics by 4.4% during the third quarter. Dimensional Fund Advisors LP now owns 3,580,081 shares of the company’s stock valued at $129,527,000 after purchasing an additional 149,865 shares during the last quarter. Thrivent Financial For Lutherans increased its stake in Myriad Genetics by 7,026.7% during the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock valued at $70,862,000 after purchasing an additional 2,703,860 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Myriad Genetics by 31.1% during the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock valued at $33,400,000 after purchasing an additional 306,276 shares during the last quarter.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.